Beleggen.nl
Uitgebreid zoeken
Markt MonitorMarkt Monitor

BioPharma Terug naar discussie overzicht

INSM - Insmed - 2009 draadje

3.044 Posts
Pagina: «« 1 ... 3 4 5 6 7 ... 153 »» | Laatste | Omlaag ↓
  1. [verwijderd] 13 mei 2009 19:24

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    crackedtooth schreef:

    [quote=Rieltijm]
    [quote=crackedtooth]
    En ook:
    Opinies over market cap van insmed
    www1.investorvillage.com/smbd.asp?mb=...

    [/quote]
    Heb mijn post met link van PR weggehaald, dubbel hoeft ook niet. Nog een mening, Crack..?
    [/quote]

    iedereen deze lezen svp.. los van koers gekloot

    @rietlijm: wat bedoel je verder?
    Eigenlijk je idee over het verdere verloop. Nu tijdens de CC geen info over eigenlijk alle lopende en belangrijke zaken. In de planning nog steeds 2e kwartaal info aangaande MMD, maar zoals ze zelf expliciet zeggen echt de planning. Kan natuurlijk altijd later worden, maar doet de koers ook niet echt goed.

    Oftewel: wanneer gaan we echt een keertje los..

    Rietlijm
  2. [verwijderd] 13 mei 2009 19:31

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Persoonlijk zie ik bedrijf wel voor de 20e MMD data releasen, of ze dat redden is een 2e.

    Om andere assets te kopen is een zeer goede strategie en kan zeer waardevermeerderen werken.

    Market cap staat of valt met MMD resultaten.
    Ik wacht daar gedulidg op.

    PS als je twijfelt en wilt kopen zou ik op dag als vandaag rustig al wat kopen en in hapjes verspreiden deze week. kan evt 1,16-1,21 toe, maar aan andere kant kan runup voor MMD ook beginnen.|laatse plukje (klein) was op 1,39 voor mij
  4. [verwijderd] 14 mei 2009 18:24

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    Rieltijm schreef:

    Crack, data vóór de 20e ? Bedoel je dan 20 mei al ?Onderbuikgevoel of heeft het te maken met het schema van de FDA..?

    Thanx
    RT
    dan kan het bedrijf van de annual meeting een cheer event maken

    maar nogmaals, links of rechtsom duurt het niet lang meer
    dit kwartaal is gister nogmaals bevestigd
  5. [verwijderd] 15 mei 2009 11:10

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    JOHN REID BLACKWELL TIMES-DISPATCH STAFF WRITER
    Published: May 15, 2009

    At a time when many small biotechnology firms are struggling to stay afloat, Richmond-based Insmed Inc. is in the enviable position of being a newly cash-rich company.

    Thanks to the sale of some of its biotech drug candidates in March, the biopharmaceutical company has received a cash infusion of $125 million. That's a huge turnaround from the $2.4 million in cash the company had on hand in late December, when it was burning through about $1.2 million per month.

    Insmed executives say the deal, which came after two years of work and struggles for the company, gives it a war chest to hunt for new growth opportunities, possibly by acquiring drug candidates from other biotech companies that are facing financial distress in the economic downturn.

    "It's a tribute to the tenaciousness with which we've run our business over the years," said Geoffrey Allan, the company's president and chief executive officer. "Two years ago, we could have folded the tent. We didn't do that."

    The money also gives Insmed a cash buffer while it continues to test one of its key drugs, Iplex, for treatment of myotonic muscular dystrophy, a genetic, muscle-wasting disease that affects about 30,000 Americans.

    The timing of the deal also was important, coming just as the financial crisis has made it more difficult for biotechnology firms to raise money. About 30 percent of publicly traded biotech companies have less than six months' worth of cash on hand, while 45 percent have less than one year, according to a recent report by the Biotechnology Industry Organization, a national trade group.

    "I would definitely say that Insmed is in a unique position of having significant resources on hand," said Mark Herzog, executive director of the Virginia Biotechnology Association.

    "The vast majority of companies I speak to are really struggling with only having enough cash on hand to last three to six months," Herzog said. "Insmed is very well-placed to be able to continue their research and development efforts."

    The deal is the latest in a series of twists and turns for Insmed, which was founded in Charlottesville in 1988 to develop diabetes drugs.

    In 1995, the company became one of the first tenants of the Virginia BioTechnology Research Park in downtown Richmond. It has since moved its corporate office to Stony Point Parkway in South Richmond.

    The company has taken its share of lumps in recent years, most notably in 2007, when Insmed settled a patent-infringement lawsuit filed by a competitor, which forced it to remove Iplex from the market for treatment of a rare growth disorder in children.

    The settlement allowed Insmed to continue developing and marketing Iplex for other illnesses such as muscular dystrophy and Lou Gehrig's disease, but the lawsuit "had a fairly devastating effect on our business," Allan said.

    In the past couple of years, the company suffered from cash-flow issues and fought to keep its shares listed on the Nasdaq stock exchange.

    Setbacks come with the territory in biotech, where the outcome of product research is uncertain and financial backing is often difficult to obtain.

    "I think we are pretty battle-hardened here in terms of what we have gone through," said Kevin Tully, the company's executive vice president and chief financial officer. "You are always in the situation where you are having to finish a clinical trial, manufacture a drug, and look for cash to support it. You are constantly having to adjust. As a small company, we have been able to do that. We don't have a lot of bureaucracy."

    After the lawsuit settlement, Allan said, "we essentially circled the wagons and figured out what we were good at, and how to deploy the resources we had available to survive that particular blow."

    Insmed's strategic solution in 2007 was to move into follow-on biologics, an area of research in developing and making generic versions of drugs produced through biological processes. The company was successful at developing several experimental versions of drugs used in therapies for cancer patients.

    The strategy paid off in February when pharmaceutical company Merck & Co Inc. agreed to buy Insmed's follow-on biologics platform for $130 million. Insmed said it will have about $125 million from the deal after fees and taxes.

    On Wednesday, Insmed reported a first-quarter profit of $117.8 million, compared with a loss of $4.9 million in the same period of 2008. The turnaround was largely because of the sale of its follow-on biologics business to Merck.

    The deal also makes Insmed a much leaner company, with just 20 employees at its Richmond office. Its Boulder, Colo., facility, which employs 70 people, was sold as part of the Merck deal.

    The company's next step is to complete testing on its Iplex drug for muscular dystrophy, which has no other drug treatment.

    "We are, in many ways, pioneering development in that area," said Glen L. Kelley, the company's vice president for regulatory affairs. Though the outcome is still uncertain, "it is a great place for a company like Insmed to spend time developing drugs, because it is a niche opportunity."

    Insmed executives said they are also going to carefully evaluate other opportunities such as acquisitions of potential drugs that are in the late stage of development that would help the company become profitable for the long term.

    "Can we repeat the exercise and in two years have a very positive outcome?" Allan said. "I can't guarantee it, but we will all work towards it."

    www.timesdispatch.com/rtd/business/lo...

    Grtz CV
  10. [verwijderd] 17 mei 2009 08:58

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    junkbond schreef:

    The New York Times

    www.nytimes.com/2009/05/17/health/pol...
    Eigenlijk te gek voor woorden dat Iplex door een patent-kwestie van de markt is gehaald en hierdoor duizenden patienten zonder het door hen gewenste (en noodzakelijke !) medicijn zitten..

    Kathy found another doctor to prescribe the drug, called Increlex. But she cried later when she read a blog entry by an A.L.S. patient who said he had experienced a “seismic” improvement on Iplex before it was withdrawn. The Increlex shots he was taking now felt like “trying to get drunk on cough syrup when there’s a case of bourbon locked in the closet,” he wrote.

    Jammer dat er nog zat mensen op beslissende functies zitten die de menselijke kant van een verhaal niet kennen (of niet willen kennen). Als je het verhaal in de NYT leest kan je alleen je hoofd schudden..

    Riel T.
  13. [verwijderd] 17 mei 2009 21:34

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Front page blijkbaar

    3.bp.blogspot.com/_z5MZ_agGgNc/Sg_yIt...

    en word op veel plaatsen overgenomen:
    Columbus, Ohio www.dispatch.com/live/content/nationa...

    www.theledger.com/article/20090516/NE...

    www.blueridgenow.com/article/20090517...

    www.starnewsonline.com/article/200905...

    Tuscala, AL www.tuscaloosanews.com/article/200905...

    Wilmington, MC www.starnewsonline.com/article/200905...
  18. [verwijderd] 18 mei 2009 11:59

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    gismo74 schreef:

    seekingalpha.com/article/138180-will-...

    En nog een stukje!
    Mooi gevonden !

    If results (MMD) are positive, the Insmed stock could breach the $2.50 mark, or higher, based on the potential of IPLEX. The trading pattern of INSM over the past couple of weeks has me believing that news is imminent, and I do not believe that the recent rise to $1.50 is strictly the result of the pending quarterly report.

    en:

    Based on the fact that IPLEX is an already FDA-approved drug with huge potential, I believe INSM is a five dollar stock right now. If quarter two produces solid Phase II MMD results and any additional good news, I would expect to the stock reach that level by mid summer (give or take) as the economy rebounds and money pours back into the market.

  20. [verwijderd] 18 mei 2009 14:21

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    Rieltijm schreef:

    Pre-Market

    Price Pre-Market / Share Volume
    07.15 $ 1.54 / 400
    06.05 $ 1.49 / 400

    Ziet er toch leuk uit ondanks een volume van nix....
    Dit lijkt er al meer op....
    Volume 27.280 en high 1,60. Nu 1,55....
  21. [verwijderd] 18 mei 2009 14:21

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    Rieltijm schreef:

    Pre-Market

    Price Pre-Market / Share Volume
    07.15 $ 1.54 / 400
    06.05 $ 1.49 / 400

    Ziet er toch leuk uit ondanks een volume van nix....
    Volume 20K en $ 1.59
    Normaal hecht ik geen directe waarde aan voorbeurs.... nu twijfel ik of ik dit niet wel moet doen ;-)
3.044 Posts
Pagina: «« 1 ... 3 4 5 6 7 ... 153 »» | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Beleggen.nl

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.012
AB InBev 2 5.495
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 51.510
ABO-Group 1 22
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 264
Accsys Technologies 23 10.582
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 188
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.723
Aedifica 3 903
Aegon 3.258 322.686
AFC Ajax 538 7.087
Affimed NV 2 6.289
ageas 5.844 109.887
Agfa-Gevaert 14 2.049
Ahold 3.538 74.330
Air France - KLM 1.025 35.022
AIRBUS 1 11
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.036
Alfen 16 24.687
Allfunds Group 4 1.469
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 405
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.819
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.836 242.913
AMG 971 133.197
AMS 3 73
Amsterdam Commodities 305 6.687
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 490
Antonov 22.632 153.605
Aperam 92 14.974
Apollo Alternative Assets 1 17
Apple 5 381
Arcadis 252 8.767
Arcelor Mittal 2.033 320.656
Archos 1 1
Arcona Property Fund 1 286
arGEN-X 17 10.292
Aroundtown SA 1 219
Arrowhead Research 5 9.729
Ascencio 1 26
ASIT biotech 2 697
ASMI 4.108 39.088
ASML 1.766 106.396
ASR Nederland 21 4.452
ATAI Life Sciences 1 7
Atenor Group 1 485
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 13.647
Axsome Therapeutics 1 177
Azelis Group 1 64
Azerion 7 3.392